News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
137 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33091)
2026 (17234)
Month
January (2936)
February (2968)
March (2710)
April (2908)
May (3626)
June (2409)
July (2088)
August (2590)
September (2381)
October (3064)
November (3189)
December (2222)
Day
2 (201)
3 (125)
4 (118)
5 (124)
6 (51)
9 (127)
10 (94)
11 (130)
12 (125)
13 (61)
16 (159)
17 (116)
18 (142)
19 (70)
20 (35)
23 (191)
24 (140)
25 (137)
26 (112)
27 (81)
30 (70)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
2
3
4
5
6
9
10
11
12
13
16
17
18
19
20
23
24
25
26
27
30
Business
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean many companies are unlikely to ever recoup their investments.
June 25, 2025
·
5 min read
·
Nick Paul Taylor
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of clear differentiation” for rezpegaldesleukin in the atopic dermatitis space.
June 25, 2025
·
3 min read
·
Tristan Manalac
Duchenne muscular dystrophy
FDA Reviews Sarepta’s Elevidys After Second Patient Death
The FDA is assessing the need for “further regulatory action” on Sarepta’s Duchenne muscular dystrophy gene therapy in the aftermath of two patient deaths, though the regulator has not yet specified what action this could be.
June 25, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.
June 25, 2025
·
2 min read
·
Tristan Manalac
Career Advice
Leadership Lab: 5 Ways Biopharma Execs Can Restore Trust, Retain Talent After Layoffs
In the latest installment of his column, Kaye/Bassman’s Michael Pietrack shares five ways leaders can help their teams after a layoff, from acknowledging emotions to reestablishing culture.
June 25, 2025
·
4 min read
·
Michael Pietrack
Job Search Strategy
Finding Your Next Role: 5 Ways To Uncover Hidden Jobs
Tapping into the hidden job market can be challenging but is important in today’s employer-driven market. Three talent acquisition experts share tips for accessing hard-to-find roles.
June 25, 2025
·
5 min read
·
Angela Gabriel
FDA
FDA Names Psychedelic Proponent as CDER Deputy Director, Top Spot Remains Open
Mike Davis previously worked as clinical team leader at the FDA’s Division of Psychiatry before serving as chief medical officer for Usona Institute, a research organization advancing psychedelic science.
June 25, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH PATSNAP
Webinar: Beyond Theory: Real-World AI Wins in Life Science R&D, Faster & Smarter
Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the fast-evolving life science landscape, AI is no longer a luxury, it’s a necessity.
June 25, 2025
·
1 min read
·
BioSpace Insights
Vaccines
What To Watch for as ACIP’s New Era Begins
The newly appointed members of the CDC’s influential vaccine committee meet Wednesday and Thursday under an unusually rapid timeline, with unexpected topics on the agenda.
June 25, 2025
·
3 min read
·
Dan Samorodnitsky
GLP-1
Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be three times larger than what AbbVie’s blockbuster Humira ever achieved.
June 25, 2025
·
3 min read
·
Annalee Armstrong
1 of 14
Next